iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
iSpecimen (Nasdaq: ISPC) priced a public offering of approximately $5 million of common stock and/or pre-funded warrants at a public offering price of $1.30 per share, or $1.2999 per pre-funded warrant, reflecting the $0.0001 per share exercise price of each pre-funded warrant.
According to iSpecimen, net proceeds are expected to be used to repay outstanding liabilities, fund potential asset or business acquisitions, support investments in products and technologies, and pay for marketing and advertising services, with the remainder allocated to working capital. E.F. Hutton & Co. is acting as exclusive placement agent. The offering is expected to close on August 7, 2026, subject to customary conditions, under an effective SEC Form S‑1 registration statement.
Positive
- Approximate $5 million offering to fund liabilities, acquisitions, and growth initiatives
- Offering price set at $1.30 per share, providing transparent terms for investors
- Proceeds earmarked for debt repayment, marketing, and working capital support
- Exclusive placement agent E.F. Hutton & Co. engaged to manage the transaction
Negative
- Equity and pre-funded warrant issuance implies potential dilution for existing shareholders
- Use of proceeds includes repayment of outstanding liabilities, highlighting current obligations on the balance sheet
News Explained
Completion would add dilution exposure to existing holders, while the approximately $5 million gross offering equals 133.9 days of last quarter’s operating cash use.
The priced offering is not yet closed; if common stock is issued or pre-funded warrants are exercised, additional shares would increase total share count and reduce existing holders’ percentage ownership, while the company would receive the offering proceeds.
Pre-funded warrants are sold at nearly the full share price with a nominal exercise price and convert into shares when exercised, so this form postpones share issuance until exercise rather than removing the ownership effect.
Against iSpecimen’s latest reported quarter ended
Sources and calculations
- iSpecimen public offering pricing release (2026-08-06)
- Dilution definition (undated)
- Pre-funded warrant definition (undated)
- iSpecimen 2026 first-quarter fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $5,000,000 / ($3,361,846 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $2,818,989 / ($3,361,846 / 90) = [object Object]
Market reaction after 5M public offering: ISPC +16.15%
Following this news, ISPC has gained 16.15%, reflecting a significant positive market reaction. Our momentum scanner has triggered 18 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $2.23. Trading volume is elevated at 2.9x the average, suggesting notable buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 30 | public offering pricing | Negative | +2.4% | Pricing of a $5 million offering preceded a 2.37% positive reaction. |
| Oct 31 | public offering closing | Negative | -0.9% | Closing of a $5 million offering preceded a 0.93% negative reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-tagged history was mixed: one pricing announcement preceded a positive reaction and one closing preceded a negative reaction, producing a 0.72% average move.
Key Terms
pre-funded warrants financial
placement agent financial
registration statement regulatory
form s-1 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of its public offering of approximately
E.F. Hutton & Co. is acting as the exclusive placement agent in connection with the offering.
The offering is expected to close on August 7, 2026, subject to customary closing conditions. The securities described above are being offered pursuant to the Company’s registration statement on Form S-1 (File No. 333-297001) (the “Registration Statement”), initially filed with the Securities and Exchange Commission (the “SEC”) on June 24, 2026, and subsequently declared effective by the SEC on July 30, 2026. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A preliminary prospectus relating to the offering has been filed with the SEC. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at https://www.sec.gov/. Copies of the final prospectus relating to this offering, when available, may be obtained from E.F. Hutton & Co., 745 Fifth Avenue, 34th Floor & PH, New York, NY 10151.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate,” “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
